REG - Ergomed plc - Share Options
RNS Number : 7257CErgomed plc19 June 2019PRESS RELEASE
Ergomed Award of Share Options and Award of Options by Executive Chairman Over Personally Owned Shares
Guildford, UK - 19 June 2019: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, today announces that the following LTIP (Long Term Incentive Plan) awards have been made to newly-appointed CFO Richard Barfield.
The awards consist of share options over the Company's ordinary shares having a nominal value of 1 pence each (the "Options") with an exercise price of 1 pence per share. Of the total, 200,000 will vest after three years of the commencement of Richard Barfield's employment with the Company and are not subject to performance criteria. The remaining 400,000 are subject to performance criteria and vest as follows: 200,000 will vest dependent on total shareholder return of 15% per annum over three years; an additional 100,000 will vest dependent on total shareholder return of 25% per annum over three years; and an additional 100,000 will vest dependent on total shareholder return of 35% per annum over three years.
In total, 600,000 Options were granted on 18 June 2019, representing 1.3 per cent. of the issued share capital.
In addition, Dr Miroslav Reljanović, Executive Chairman of Ergomed, has granted options over 400,000 ordinary shares from his personal holding to Mr Barfield. Of the total, 100,000 will vest after three years of the commencement of Richard Barfield's employment with the Company and are not subject to performance criteria; an additional 100,000 will vest dependent on total shareholder return of 15% per annum over three years; an additional 100,000 will vest dependent on total shareholder return of 25% per annum over three years; and an additional 100,000 will vest dependent on total shareholder return of 35% per annum over three years.
The 400,000 ordinary shares over which Dr Reljanović has granted options will remain in his personal holding until exercise. Dr Reljanović is interested in 10,955,767 ordinary shares of the Company, representing 23.5 per cent. of the issued share capital.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Dr Miroslav Reljanović
2
Reason for the notification
a)
Position/status
Founder and Executive Vice-Chairman
b)
Initial notification /Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Ergomed Plc
b)
Legal Entity Identifier
213800BVS8I9VMC1AP84
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary shares of 1 pence each
GB00BN7ZCY67
b)
Nature of the transaction
Grant of options over a proportion of his personal shareholding.
c)
Currency
GBP
d)
Price(s) and volume(s)
Price(s)
Volume(s)
1 pence
400,000
e)
Aggregated information
- Aggregated volume
- Price
- Aggregated total
400,000 ordinary shares at an exercise price of 1 pence per share.
f)
Date of the transaction
18 June 2019
g)
Place of the transaction
Outside a trading venue.
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Richard Barfield
2
Reason for the notification
a)
Position/status
Chief Financial Officer
b)
Initial notification /Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Ergomed Plc
b)
Legal Entity Identifier
213800BVS8I9VMC1AP84
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary shares of 1 pence each
GB00BN7ZCY67
b)
Nature of the transaction
Grant of options under the Company's Long Term Incentive Plan
c)
Currency
GBP
d)
Price(s) and volume(s)
Price(s)
Volume(s)
1 pence
1,000,000
e)
Aggregated information
- Aggregated volume
- Price
- Aggregated total
1,000,000 ordinary shares at an exercise price of 1 pence per share.
f)
Date of the transaction
18 June 2019
g)
Place of the transaction
Outside a trading venue.
Enquiries:
Ergomed plc
Tel: +44 (0) 1483 402 975
Miroslav Reljanović (Executive Chairman)
Numis Securities Limited
Tel: +44 (0) 20 7260 1000
Freddie Barnfield / Huw Jeremy (Nominated Adviser)
James Black (Broker)
Consilium Strategic Communications - for UK enquiries
Tel: +44 (0) 20 3709 5700
Chris Gardner / Mary-Jane Elliott
ergomed@consilium-comms.com
Matthew Neal / Olivia Manser
MC Services - for Continental European enquiries
Tel: +49 211 5292 5222
Anne Hennecke
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, and a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDDSHEKLBFKQFEBBV
Recent news on Ergomed
See all newsREG - Ergomed plc - Cancellation of admission to trading of shares
AnnouncementREG - AIM Ergomed plc - Cancellation - Ergomed plc
AnnouncementREG - Takeover Panel - Disclosure Table
AnnouncementREG-Millennium Partners, L.P. Form 8.3 - Ergomed plc
AnnouncementREG - BlackRock Group Ergomed plc - Form 8.3 - Ergomed plc
Announcement